Spyre Therapeutics (SYRE) Current Deferred Revenue (2016 - 2023)
Spyre Therapeutics (SYRE) reported Current Deferred Revenue of $930000.0 for Q2 2023, up 210.0% on a YoY basis from $300000.0 in Q2 2022, and up 207.95% quarter-over-quarter from $302000.0 in Q1 2023.
Spyre Therapeutics (SYRE) Current Deferred Revenue (2016 - 2023) Analysis & Trends
Spyre Therapeutics has reported Current Deferred Revenue for 5 years, with the latest figure at $930000.0 in Q2 2023.
- For the quarter ending Q2 2023, Current Deferred Revenue rose 210.0% year-over-year to $930000.0; the trailing twelve-month figure through Jun 2023 stood at $930000.0 (up 210.0% YoY), and the FY2022 full-year result was $2.7 million, up 14.29% from the prior year.
- Current Deferred Revenue for Q2 2023 stood at $930000.0, up from $302000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $21.5 million in Q1 2021, with the low at $300000.0 in Q2 2022.
- Historically, Current Deferred Revenue has averaged $4.3 million across 3 years, with a median of $2.2 million in 2021.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue slumped 94.55% — and 2023, when it soared 210.0%.
- Spyre Therapeutics' Current Deferred Revenue stood at $2.4 million in 2021, then increased by 14.29% to $2.7 million in 2022, then slumped by 65.5% to $930000.0 in 2023.
- The last three Current Deferred Revenue figures came in at $930000.0 (Q2 2023), $302000.0 (Q1 2023), and $2.7 million (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 930,000.00 |
| Mar 31, 2023 | 302,000.00 |
| Dec 31, 2022 | 2.70 Mn |
| Sep 30, 2022 | 505,000.00 |
| Jun 30, 2022 | 300,000.00 |
| Mar 31, 2022 | 2.10 Mn |
| Dec 31, 2021 | 2.36 Mn |
| Sep 30, 2021 | 6.40 Mn |
| Jun 30, 2021 | 5.50 Mn |
| Mar 31, 2021 | 21.50 Mn |
| Dec 31, 2017 | 20,000.00 |
| Sep 30, 2017 | 50,000.00 |
| Jun 30, 2017 | 71,000.00 |
| Mar 31, 2017 | 51,000.00 |
| Dec 31, 2016 | 71,000.00 |
| Sep 30, 2016 | 181,000.00 |